Fox Christine 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Nov 21, 2024
Insider Transaction Report
Form 4
Fox Christine
EVP, U.S. Commercial
Transactions
- Exercise/Conversion
Ordinary Shares
2024-11-20+63,492→ 63,492 total - Sale
Ordinary Shares
2024-11-20$16.87/sh−19,388$327,085→ 44,104 total - Exercise/Conversion
Restricted Share Units
2024-11-20−63,492→ 190,476 total→ Ordinary Shares (63,492 underlying)
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2024.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]Restricted share units were granted on November 20, 2023, with 63,492 vested on November 20, 2024, and 63,492 vesting on each of November 20, 2025, November 20, 2026 and November 20, 2027.